17,261 trials
Metastatic Pancreatic Cancer
Primary: Percentage of Patients Alive and Without Radiological and/or Clinical Progression 6 Months After the Randomization. — 41; 39; 30 Participants
Colorectal Neoplasms
Primary: The Primary Objective Was the Percentage of Patients Alive and Without Progression 6 Months After the Randomization. — 30; 30; 26; 26 Participants
Advanced Melanoma · Triple-Negative Breast Cancer
Primary: The Primary Efficacy Endpoint Was ORR, Defined as the Proportion of Subjects Demonstrating CR or PR Based on RECIST v1.1 Criteria. — 1; 1; 0; 5 Participants
Alpha-1 Antitrypsin Deficiency (AATD) · Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations · Emphysema or COPD
Primary: Within-individual % Change in Plasma Desmosine/Isodesmosine — 10.0619; 8.5627 % change
Metastatic Pancreatic Cancer
Primary: Percentage of Patients Alive and Without Radiological and/or Clinical Progression 6 Months After the Randomization — 28; 14 Participants
Breast Cancer · Breast Cancer Stage IV · HER2-negative Breast Cancer
Primary: Dose Limiting Treatment/DLT Evaluable Population
Medullary Thyroid Cancer (MTC)
Primary: Calcitonin Growth Rate — -2.53; -2.49 days^-1 — p=0.3760
Alzheimer Disease
Primary: Change in fMRI — 11 Participants
Positron-Emission Tomography · Metastatic Solid Tumors
Primary: Correlation of ⁸⁹Zr-Df-IAB22M2C Uptake in Biopsied Tumors With CD8+ Cell Measurement by Immunohistochemistry (IHC) — 0.3902; 0.7848 r
Alzheimer's Disease
Primary: Computerized Neuropsychological Test Battery (cNTB) Z-Scores - Change From Baseline — 0.0434; 0.1175; 0.0297; 0.0591 z-score
Triple Negative Breast Cancer · Breast Neoplasms
Primary: Safety and Tolerability Adverse Events — 8; 81 Total events
Covid19
Primary: Change From Baseline in High-sensitivity Troponin T — 1.12; 1.01 ng/mL — p=0.29
Urothelial Carcinoma
Primary: Objective Response Rate — 8.3 Percentage of participants
Colitis, Ulcerative
Primary: Exposure Adjusted Rate of Participants Reporting a Treatment Emergent Adverse Event (TEAE) — 260.6 Events per 100 patient-years
Hematopoietic and Lymphoid Cell Neoplasm · Malignant Solid Neoplasm · Symptomatic COVID-19 Infection Laboratory-Confirmed
Primary: Maximum Tolerated Dose (MTD) (Phase 1) — NA mg